Amelenodor is a small molecule commercialized by AbbVie, with a leading Phase II program in Ulcerative Colitis. According to Globaldata, it is involved in 4 clinical trials, of which 2 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Amelenodor’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Amelenodor is expected to reach an annual total of $14 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Amelenodor Overview
Amelenodor (NX-13) is under development for the treatment of inflammatory bowel disease including ulcerative colitis and Crohn's disease. The drug candidate is administered through oral route in the form of tablet as a once-daily formulation. It acts by targeting NLR family member X1(NLRX1). The drug candidate is being developed based on artificial intelligence (AI) technology platform.
AbbVie Overview
AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic and rheumatological diseases, neurological disorders, skin diseases, rheumatoid arthritis, pain related to endometriosis, pediatric Crohn’s disease, cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of Crohn’s disease, Parkinson’s disease, neurological disorders, aesthetics, and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, healthcare facilities, government agencies, specialty pharmacies, and independent retailers. The company has operations in the Americas, Asia-Pacific, Europe, the Middle East and Africa. AbbVie is headquartered in North Chicago, Illinois, the US.
The company reported revenues of (US Dollars) US$54,318 million for the fiscal year ended December 2023 (FY2023), a decrease of 6.4% over FY2022. In FY2023, the company’s operating margin was 23.5%, compared to an operating margin of 31.2% in FY2022. In FY2023, the company recorded a net margin of 9%, compared to a net margin of 20.4% in FY2022.
The company reported revenues of US$12,310 million for the first quarter ended March 2024, a decrease of 13.9% over the previous quarter.
For a complete picture of Amelenodor’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.